Novo Nordisk Accelerates FDA Filing of Oral GLP-1 Therapy Amid Intensifying Competition with Eli Lilly

Local time4Month21On [date], Novo Nordisk announced that it had submitted to the United StatesFDASubmit Oral VersionGLP-1The marketing application for the weight-loss drug. This medication is its injectable weight-loss solution.WegovyThe oral version of (semaglutide) is...2023Year5Key Announcement in Month3It has been nearly two years since the successful outcome of the clinical trial.

According to the trial data, the highest dose of oral semaglutide (50mg) Group patients in64Weight loss within the week15%. Although Novo Nordisk had planned to2023Submit the application by the end of the year, but restricted by the circumstances at that time.WegovyAnd Diabetes DrugsOzempicThe production capacity bottleneck has forced the priority of oral dosage form production to give way to injectable supply. A company spokesperson revealed that more details will be provided in5Month7Disclosed in the quarterly earnings report.

 Capacity Dilemma and Pipeline Adjustment: Novo Nordisk's "Sweet Troubles"

AsGLP-1The leading company in the field, Novo Nordisk, has been deeply troubled by "production capacity anxiety" in recent years. Its star productWegovyAndOzempicDue to the explosive demand for weight loss and sugar control, global sales continue to soar.2023YearOzempicSales Breakthrough200billion dollars. However, difficulties in ramping up production have led to frequent stockouts in many parts of the world, forcing the company to prioritize injectable production, which has thus delayed the development progress of oral semaglutide.

At the same time, Novo Nordisk's bet on the "next generation of weight loss wonder drugs"-Dual-target drugCagriSema（GLP-1/GIPDual agonist) has recently encountered a Waterloo.3Published in the month of2The Phase clinical trial showed that the highest dose group only achieved16%The weight loss was much lower than previously advertised.25%Expected. After the announcement, Novo Nordisk's stock price plummeted.36%, the market's confidence in its pipeline competitiveness was undermined.

 Lilly "Pursuers" Close In: OralGLP-1The Track Fills with Smoke

Novo Nordisk Accelerates Approval of Oral Semaglutide in Response to Competitor Eli LillyGLP-1DrugorforglipronShining in clinical trials, its data directly impacted the market's confidence in Novo Nordisk's dual-target drug. Previously, the industry generally believedCagriSemaMay become a benchmark in the oral weight loss market. As Novo Nordisk's dual-target drug loses its luster, the two major pharmaceutical companies will compete directly in the single-target market.GLP-1Competition in the oral medication field intensifies.

Notably, Novo Nordisk already has an oralGLP-1DrugRybelsus(Semaglutide Oral Tablets,7mg/14mgDosage form) for the treatment of diabetes,2023Annual sales reached233Million Danish Kroner (approximately34USD billion), year-on-year growth26%. Three weeks ago, Novo Nordisk had justRybelsusSubmit an indication expansion application, intended for reducing cardiovascular disease risk, further expanding market boundaries.

 Industry Watch: Can Oral Formulations Replicate the Success of Injectables?

GLP-1The launch of oral formulations will reshape the weight-loss drug market. Compared to injectables, oral medications have significant advantages in terms of patient compliance and ease of use, potentially attracting users who are mildly obese or privacy-conscious. However, oral semaglutide requires daily dosing (injectableWegovyOnce a week), and50mgHigh-dose formulations have a higher incidence of gastrointestinal side effects (such as nausea, diarrhea), which may affect market acceptance.

Currently,FDAFor oral useGLP-1The approval criteria for the drug have not been fully clarified, especially regarding long-term safety data and cardiovascular benefits. Can Novo Nordisk seize the market with its first-mover advantage, and what about Eli Lilly'sorforglipronWhat stance will it take to enter the game, this "oral battle" is expected to become2025The Biggest Highlight of the Annual Weight Loss Drug Market.

Novo Nordisk's submission this time is not only a response to the capacity challenge but also a key layout to address the competition from Eli Lilly. In the current market dominated by injectables, oralGLP-1Can drugs open up new growth poles? As two major giants accelerate their entry, the "oral revolution" in the weight-loss drug market may have just begun.

This article is compiled fromFiercePharma

●Personnel Changes in Novartis China Management!

●Eisai/Biogen's Leqembi Successfully Passes EU Approval, Leaving Lilly and Others Behind...

●China's National Medical Products Administration Takes Action! Five Drugs Halted, Involving Sinopharm, Hayao...